[{"orgOrder":0,"company":"Cell Therapies","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Cell Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cell Therapies \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Cell Therapies \/ Novartis"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Oxford Biomedica \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Oxford Biomedica \/ Novartis"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Perelman School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Perelman School of Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Perelman School of Medicine"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"Human IL-7","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneTech \/ Not Applicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"Denileukin Diftitox","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"}]

Find Clinical Drug Pipeline Developments & Deals for Tisagenlecleucel

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Citius intends to use proceeds for the pre-clinical and clinical development of Lymphir (denileukin diftitox), a recombinant fusion protein combining interleukin-2 and diphtheria toxin.

                          Brand Name : Lymphir

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 26, 2024

                          Lead Product(s) : Denileukin Diftitox,Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $15.0 million

                          Deal Type : Private Placement

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Lymphir™ (denileukin diftitox) in combination with FDA-approved CAR-T products like tisagenlecleucel or lisocabtagene maraleucel is being investigated for relapsed or refractory B-cell lymphomas.

                          Brand Name : Lymphir

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 11, 2024

                          Lead Product(s) : Denileukin Diftitox,Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit.

                          Brand Name : NT-I7

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 04, 2022

                          Lead Product(s) : Efineptakin Alfa,Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : 44% of patients who experienced remission within three months of infusion were still in remission at the five-year mark, demonstrating the long-term benefit and curative potential of one-time Kymriah (Tisagenlecleucel) infusion.

                          Brand Name : Kymriah

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 12, 2022

                          Lead Product(s) : Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Perelman School of Medicine

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The approval of Kymriah (Tisagenlecleucel) is based on data from the Phase II ELARA trial, a single-arm, open-label trial, in which 90 patients were evaluated for efficacy with a median follow-up of approximately 17 months.

                          Brand Name : Kymriah

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 27, 2022

                          Lead Product(s) : Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Approval based on the Phase II ELARA trial showing Kymriah (tisagenlecleucel) demonstrated high response rates in heavily pretreated patients, including an 86% overall response rate and a 69% complete response.

                          Brand Name : Kymriah

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 04, 2022

                          Lead Product(s) : Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : CHMP opinion based on Phase II global ELARA trial for Kymriah, demonstrating high response rates in heavily pretreated patients; 69% experienced a complete response, with an 86% overall response rate and a remarkable safety profile.

                          Brand Name : Kymriah

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          March 25, 2022

                          Lead Product(s) : Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : CAR T-cell therapy tisagenlecleucel (tisa-cel) was not found to improve event-free survival over what was seen with standard of care as a second-line treatment for patients with aggressive non-Hodgkin lymphoma.

                          Brand Name : Kymriah

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          December 14, 2021

                          Lead Product(s) : Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the agreement, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials with also allowing for payments for the manufacture and supply of lentiviral vectors fo...

                          Brand Name : Kymriah

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 13, 2021

                          Lead Product(s) : Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Kymriah (tisagenlecleucel) is an autologous, immunocellular cancer therapy which involves reprogramming a patient's T-cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing cells. It is administered as...

                          Brand Name : Kymriah

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 27, 2021

                          Lead Product(s) : Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank